Article Text

Download PDFPDF


Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

There were several errors in an article published in the November 2008 issue of the journal (Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–23). The final footnote in table 3 should read: “Changes according to ATPIII guidelines reflect last observation recorded within the study.” This footnote refers to the HDL and LDL within table 3, but not to cholesterol (that is baseline and week 24). Therefore the footnote should be attached to the last two categories, not the overall “Summary of changes in lipid parameters”. Also, in table 3 “Summary of changes in lipid parameters” has been mistakenly indented, possibly leading readers to believe that it is part of the AE section.

In figs 3A and 3B the triple asterisks for less than p<0.001 vs placebo are placed on the placebo line instead of the TCZ 8mg/kg line.

View Abstract

Linked Articles